Free tool
FAERS Monitor: Amyvid
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202008 or its brand name (Amyvid, Florbetapir F-18). Reports on generic versions are filed under their own applications.
Reports
115
Serious
23
20% of reports
Hospitalization
12
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- amyloid related imaging abnormality-oedema/effusion28
- amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits27
- headache14
- superficial siderosis of central nervous system9
- injection site pain7
- chest pain4
- fall4
- fatigue4
- nausea4
- balance disorder3
- burning sensation3
- confusional state3
- drug ineffective3
- erythema3
- false negative investigation result3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 15 |
| 2016 | 7 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 45 |
| 2024 | 6 |
| 2025 | 18 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,044 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| superficial siderosis of central nervous systemSignal | 9 | 13963.6 | 7270.1 | 104,138 |
| amyloid related imaging abnormality-microhaemorrhages and haemosiderin depositsSignal | 27 | 4725.7 | 3378.9 | 119,775 |
| amyloid related imaging abnormality-oedema/effusionSignal | 28 | 4264.7 | 3074.9 | 112,516 |
| false negative investigation resultSignal | 3 | 784.6 | 256.2 | 1,623 |
| burning sensationSignal | 3 | 7.8 | 2.6 | 12 |
| balance disorderSignal | 3 | 6.3 | 2.1 | 9 |
| injection site painSignal | 7 | 4.2 | 2.0 | 14 |
| headacheSignal | 14 | 4.1 | 2.5 | 31 |
| chest painSignal | 4 | 4.0 | 1.5 | 6 |
| confusional state | 3 | 3.4 | 1.1 | 3 |
| erythema | 3 | 2.7 | 0.9 | 2 |
| fall | 4 | 2.2 | 0.8 | 2 |
| fatigue | 4 | 0.9 | 0.4 | 0 |
| nausea | 4 | 0.9 | 0.4 | 0 |
| drug ineffective | 3 | 0.4 | 0.1 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.